Kidney Cancer Scotland
EU follows US & approves Keytruda for 1st line RCC
Merck & Co/MSD’s PD-1 inhibitor Keytruda received FDA approval earlier in 2019 for use alongside Pfizer’s Inlyta (axitinib) in previously untreated patients... Read More
Ilixadencel/Sunitinib Combo Therapy; Positive Results in mRCC
A combination therapy of ilixadencel plus sunitinib (Sutent) achieved complete tumor responses in patients with metastatic renal cell carcinoma (RCC), according to... Read More
keytruda + axitinib cleared as first-line kidney cancer treatment in EU
Merck & Co/MSD’s Keytruda has added first-line kidney cancer treatment to its ever-lengthening list of approved uses in the EU. The latest... Read More
A guide for talking about advanced cancer
Advice for people living with advanced cancer, their friends and family. We are pleased to present this informative document for the benefit... Read More
Glasgow student develops model kidney that could help train cancer surgeons
The 3D model ‘looks and feels’ like a real kidney. A student has used 3D printing technology to create a model of... Read More
Innovative Research for Advanced Kidney Cancer – David Braun
Alicia Morgans and David Braun discuss his innovative research in metastatic kidney cancer which focuses on understanding and improving immunotherapies in kidney... Read More
Setbacks and Advances in RCC Treatment
Given the variability in disease aggressiveness and the lack of highly predictive biomarkers in renal cell carcinoma (RCC), nothing resembling a “one... Read More
2/1 schedual Sunitinib better than 4/2, says study
The Alternative 2/1 Schedule of Sunitinib is Superior to the Traditional 4/2 Schedule in Patients With Metastatic Renal Cell Carcinoma: A Meta-analysis. Alternate... Read More
Outcomes of patients with mccRCC treated with 2nd line VEGFR-TKI
Prior to the approval of nivolumab, a monoclonal antibody targeting programmed death-1 (PD-1), vascular endothelial growth factor-receptor tyrosine kinase inhibitors (VEGFR-TKIs), specifically... Read More
Why do I volunteer?
By Emma Clark I have chosen to volunteer with Kidney Cancer Scotland for several reasons. I believe volunteering reflects who you are... Read More
Cryoablation of Stage T1b RCC Trial Outcome
Percutaneous Cryoablation of Stage T1b Renal Cell Carcinoma: Safety, Technical Results, and Clinical. The use of percutaneous cryoablation for T1b (4.1-7.0 cm)... Read More
C-reactive protein-albumin ratio as a prognostic factor in RCC
C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma – A data from multi-institutional study in Japan. The C-reactive protein... Read More
NICE recommend nivolumab + ipilimumab combo through CDF
Bristol-Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD)... Read More
Why immunotherapy is not effective for some patients with metastatic kidney cancer
White blood cells known as B cells have been shown to be effective for predicting which cancer patients will respond to immune... Read More
EMA validates Bavencio for review in advanced RCC
The European Medicines Agency (EMA) has validated Merck’s application for Bavencio (avelumab) for the treatment of patients with advanced renal cell carcinoma... Read More
Welding Linked to Kidney Cancer
HSE issues a safety alert for welding fume exposure in kidney and lung cancer This is an alert for anyone who is,... Read More
European Commission approves nivolumab ipilimumab combo
The European Commission has approved nivolumab in combination with low-dose ipilimumab for first-line treatment of patients with intermediate and poor risk advanced... Read More
CHMP adopts a positive opinion of nivolumab + ipilimumab as 1st line treatment
Press release: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) as First-Line Treatment for Patients with... Read More
Kidney Cancer patients suffer high levels of stress
Distress Levels High Among Patients With Common Form of Kidney Cancer Many patients with renal cell carcinoma, the most common type of... Read More
Phase 2 of study reports smaller tumors
AVEO Pharmaceuticals and EUSA Pharma said the Phase 2 portion of a study evaluating a treatment for renal cell carcinoma, the most common... Read More
Contrast-enhanced ultrasound aids diagnosis of kidney cancer
An enhanced ultrasound scan of the kidney is more accurate than computed tomography and magnetic resonance imaging in predicting cancer. A 10-year... Read More
cabozantinib, new first line treatment for kidney cancer
Once-daily tablet, CABOMETYX®▼(cabozantinib), approved by NICE as a first-line treatment for adult patients with Advanced Renal Cell Carcinoma (RCC) with intermediate or... Read More
Discovery of kidney cancer driver could lead to new treatment strategy
In a study published in the journal Science, researchers led by UNC Lineberger’s Qing Zhang, PhD, suggest that ZHX2 is a potential... Read More
How ablation destroys cancer to prolong lives
A very interesting article in The Guardian (7th August 2018) relating to a much underused treatment for kidney cancer in the UK, Ablation.... Read More